The introduction of inhibitors of the cyclic GMP phosphodiesterase (PDE) 5 into clinical urology is mainly the result of the characterization of the physiology of nonvascular and vascular penile ...

Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative ...

Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and ...

ED is a medical condition in which you regularly have trouble getting or maintaining an arousal firm enough for satisfying ...

The company believes these combinations create a broader approach to treating neurodegenerative diseases ・Preclinical studies have demonstrated these combinations significant ...

The benefits do not stop there. Recent studies suggest GLP-1 drugs may also reduce the risk of heart disease, kidney disease and stroke, and even possibly protect the brain from AD by reducing ...

Alzheimer's disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received ...

Prostaglandin analogues and phosphodiesterase inhibitors, either alone or as add-on therapy, are effective treatments for vitiligo repigmentation.

Annovis is at the forefront, testing buntanetap in pivotal clinical trials as a therapy for Alzheimer's and Parkinson's diseases (PD). Company has filed three new patents protecting combinations of ...

The company has also reported positive data for PDE4 inhibitor, orismilast, in psoriasis, hidradenitis suppurativa, and ...